| scholarly article | Q13442814 |
| review article | Q7318358 |
| P6179 | Dimensions Publication ID | 1018035949 |
| P356 | DOI | 10.1007/BF02244983 |
| P698 | PubMed publication ID | 7855215 |
| P2093 | author name string | M Sarter | |
| P2860 | cites work | The effects of transdermal scopolamine and four dose levels of oral scopolamine (0.15, 0.3, 0.6, and 1.2 mg) upon psychological performance. | Q51217245 |
| Acetylcholine released from cerebral cortex in relation to state of activation | Q51226900 | ||
| High dose diazepam in schizophrenia. | Q51272045 | ||
| SOME BEHAVIORAL CHANGES IN MAN FOLLOWING ANTICHOLINESTERASE ADMINISTRATION | Q51352498 | ||
| A comparison of the effects of scopolamine and diazepam on working memory. | Q51721172 | ||
| Diazepam treatment of early symptoms of schizophrenic relapse. | Q51760133 | ||
| Memory performance in individuals with primary degenerative dementia: its similarity to diazepam-induced impairments. | Q51832043 | ||
| Adverse effects of single therapeutic doses of diazepam on performance in normal geriatric subjects: relationship to plasma concentrations. | Q51849529 | ||
| Diazepam in high doses is effective in schizophrenia. | Q51864004 | ||
| Visual controlled information processing resources and formal thought disorder in schizophrenia and mania. | Q52037616 | ||
| Amnesic syndrome in schizophrenia. | Q52055004 | ||
| Neuropsychological effects of L-deprenyl in Alzheimer's type dementia. | Q52058525 | ||
| A pilot study of haloperidol treatment of psychosis and behavioral disturbance in Alzheimer's disease. | Q52064856 | ||
| Short-term memory impairments in Alzheimer-type dementia: evidence for separable impairments of articulatory rehearsal and long-term memory. | Q52065682 | ||
| The mechanism of excitation by acetylcholine in the cerebral cortex | Q24536212 | ||
| The attention system of the human brain | Q28245431 | ||
| Gating and habituation of the startle reflex in schizophrenic patients | Q28304417 | ||
| Implications of normal brain development for the pathogenesis of schizophrenia | Q29618740 | ||
| Generalized cognitive slowing and severity of dementia in Alzheimer's disease: implications for the interpretation of response-time data | Q30954762 | ||
| Thalamic radiodensity and cognitive performance in mild and moderate dementia of the Alzheimer type. | Q33921173 | ||
| Evolving conceptions of memory storage, selective attention, and their mutual constraints within the human information-processing system | Q34048765 | ||
| Age-dependent modulation of in vivo cortical acetylcholine release by benzodiazepine receptor ligands | Q34239464 | ||
| Bidirectional modulation of stimulated cortical acetylcholine release by benzodiazepine receptor ligands | Q34348986 | ||
| Measurement and interpretation of changes in memory in response to drug treatments | Q35214298 | ||
| A review of the neurophysiological effects of lysergic acid diethylamide (LSD) and other phychotomimetic agents | Q35244471 | ||
| Antipsychotic medication effects on neuropsychological functions | Q35278876 | ||
| INPUT DYSFUNCTION IN SCHIZOPHRENIA | Q35528231 | ||
| Hippocampal function and schizophrenia. Experimental psychological evidence | Q35670906 | ||
| Cognitive alterations as markers of vulnerability to schizophrenia | Q35670908 | ||
| Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part II. | Q36204668 | ||
| Behavioral screening for cognition enhancers: from indiscriminate to valid testing: Part I. | Q36252844 | ||
| Elementary neuronal dysfunctions in schizophrenia | Q36385558 | ||
| Benzodiazepines in the treatment of schizophrenia: a review and reappraisal | Q36495525 | ||
| Benzodiazepines, memory and mood: a review | Q36535635 | ||
| Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence | Q36679262 | ||
| Cholinergic systems in mammalian brain and spinal cord | Q36882155 | ||
| Longitudinal study of the early neuropsychological and cerebral metabolic changes in dementia of the Alzheimer type. | Q52068802 | ||
| Alprazolam augmentation of the antipsychotic effects of fluphenazine in schizophrenic patients. Preliminary results. | Q52069763 | ||
| Comparison of radial maze performance of rats after ibotenate and quisqualate lesions of the forebrain cholinergic projection system: effects of pharmacological challenge and changes in training regime. | Q52072589 | ||
| Attenuation of muscarinic receptor blockade-induced impairment of spatial delayed alternation performance by the triazole MDL 26,479 | Q52081584 | ||
| Human information-processing: some effects of methylphenidate, age, and scopolamine. | Q52092187 | ||
| Information processing and attentional functioning in the developmental course of schizophrenic disorders. | Q52093199 | ||
| Improved radial maze performance induced by the benzodiazepine antagonist ZK 93 426 in lesioned and alcohol-treated rats. | Q52118048 | ||
| Scopolamine and benzodiazepine models of dementia: cross-reversals by Ro 15-1788 and physostigmine. | Q52119643 | ||
| Effects of lorazepam on memory, attention and sedation in man. | Q52127032 | ||
| Cognitive effects of L-deprenyl in Alzheimer's disease. | Q52135420 | ||
| Directed and divided attention in Alzheimer's disease: impairment in shifting of attention to global and local stimuli | Q52229420 | ||
| Physostigmine, a highly potent antidote for acute experimental diazepam intoxication. | Q52705387 | ||
| Cholinergic enhancement of direction selectivity in the visual cortex of the cat. | Q52864556 | ||
| The positive:negative dichotomy in schizophrenia. | Q52875583 | ||
| Divided attention, as measured by dichotic speech performance, in dementia of the Alzheimer type. | Q53190365 | ||
| Adverse effects of anticholinergic medication on positive schizophrenic symptoms. | Q54493472 | ||
| No response to high-dose muscarinic agonist therapy in Alzheimer's disease | Q68131098 | ||
| Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum | Q68593912 | ||
| Trihexyphenidyl abuse: therapeutic implications for negative symptoms of schizophrenia? | Q69008238 | ||
| Selective attention in Alzheimer's disease: CSF correlates of behavioral impairments | Q69047335 | ||
| Cholinergic modulation of sensory responses in rat primary somatic sensory cortex | Q69053496 | ||
| Lesions of the dorsomedial nucleus of the thalamus, medial prefrontal cortex and pedunculopontine nucleus: effects on locomotor activity mediated by nucleus accumbens-ventral pallidal circuitry | Q69118822 | ||
| Benzodiazepine augmentation of neuroleptic treatment in patients with schizophrenia | Q69377528 | ||
| Coping with attentional disorders as a systemic process in schizophrenic patients | Q69415202 | ||
| Human studies on the benzodiazepine receptor antagonist beta-carboline ZK 93,426: preliminary observations on psychotropic activity | Q69817644 | ||
| Effects of GABA compounds injected into the subpallidal regions of rat brain on nucleus accumbens evoked hyperactivity | Q69838036 | ||
| Ventral pallidum projections to mediodorsal nucleus of the thalamus: an anatomical and electrophysiological investigation in the rat | Q70173918 | ||
| Psychiatric sequelae of chronic exposure to organophosphorus insecticides | Q78847536 | ||
| Disorders of attention and perception in early schizophrenia | Q79078136 | ||
| Cholinergic hyperactivity and negative symptoms: behavioral effects of physostigmine in normal controls | Q47352870 | ||
| Crossmodal divided attention in rats: effects of chlordiazepoxide and scopolamine | Q48118558 | ||
| Cardiovascular effects of the benzodiazepine receptor partial inverse agonist FG 7142 in rats. | Q48120859 | ||
| Effects of cholinergic depletion on neuron activities in the cat visual cortex | Q48196840 | ||
| Changes in cortical acetylcholine output induced by modulation of the nucleus basalis | Q48345691 | ||
| A theory of dopamine function and its role in cognitive deficits in schizophrenia | Q48387230 | ||
| Dopaminergic regulation of cortical acetylcholine release | Q48400003 | ||
| A cancellation test: its reliability in assessing attentional deficits in Alzheimer's disease | Q48409359 | ||
| Cognitive abnormalities and schizophrenic symptoms. | Q48409373 | ||
| Scopolamine and the control of attention in humans | Q48412213 | ||
| Ibotenic acid lesion of the ventral hippocampus differentially affects dopamine and its metabolites in the nucleus accumbens and prefrontal cortex in the rat. | Q48455963 | ||
| Neurochemical studies of early-onset Alzheimer's disease. Possible influence on treatment | Q48470952 | ||
| Visuospatial attention in dementia of the Alzheimer type | Q48471573 | ||
| Convergent cholinergic activities in aging and Alzheimer's disease | Q48482922 | ||
| Failure of a chlordiazepoxide to reproduce the behavioral effects of muscimol administered into the basal forebrain | Q48493696 | ||
| Disruptive effects of muscimol infused into the basal forebrain on conditional discrimination and visual attention: differential interactions with cholinergic mechanisms | Q48560884 | ||
| Human memory and the cholinergic system. A relationship to aging? | Q48584703 | ||
| Cholinergic modulation of the functional organization of the cat visual cortex | Q48704047 | ||
| Microbehavioural analysis of the choice reaction time response in senile dementia | Q48708636 | ||
| Influence of substantia innominata neuronal activity on neocortex neuronal reactions during conditioned reflex | Q48719450 | ||
| Cell excitation enhances muscarinic cholinergic responses in rat association cortex | Q48722434 | ||
| Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors | Q48776975 | ||
| Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms | Q48911770 | ||
| Increased distractibility in schizophrenic patients. Electrophysiologic and behavioral evidence | Q49115589 | ||
| The disorder of consciousness in schizophrenia. | Q51203346 | ||
| Attention and Driving Skills in Aging and Alzheimer's Disease | Q36909208 | ||
| The effects of diisopropylfluorophosphonate in schizophrenia and manic depressive psychosis | Q37177920 | ||
| Cholinergic depletion prevents expansion of topographic maps in somatosensory cortex | Q37385043 | ||
| Significance of the positive-negative distinction in schizophrenia | Q37782970 | ||
| Activating the damaged basal forebrain cholinergic system: tonic stimulation versus signal amplification | Q37878781 | ||
| Large-scale neurocognitive networks and distributed processing for attention, language, and memory | Q38011378 | ||
| Benzodiazepines and vigilance performance: a review | Q38359870 | ||
| Cholinergic 'blockade' as a model of the cognitive deficits in Alzheimer's disease | Q38471765 | ||
| The use of semantic knowledge in Alzheimer's disease: evidence for impairments of attention | Q38477351 | ||
| Low-dose oral lorazepam administration in Alzheimer subjects and age-matched controls | Q38484784 | ||
| Diazepam-induced amnesia: a neuropharmacological model of an "organic amnestic syndrome". | Q38490119 | ||
| Controlled and automatic information processing in senile dementia: a review | Q38492048 | ||
| Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia | Q38666264 | ||
| Cholinergic involvement in mental disorders | Q38967981 | ||
| The New York High-Risk Project: anhedonia, attentional deviance, and psychopathology | Q39412944 | ||
| Anxiogenic properties of beta-CCE and FG 7142: a review of promises and pitfalls | Q39602983 | ||
| Neurochemistry of behaviour | Q40085938 | ||
| Dissociation between the effects of benzodiazepine receptor agonists on behavioral vigilance and responsitivity | Q41091828 | ||
| Further analysis of the cognitive effects of tetrahydroaminoacridine (THA) in Alzheimer's disease: assessment of attentional and mnemonic function using CANTAB. | Q41099297 | ||
| Cognitive slowing in Alzheimer's disease and geriatric depression | Q41109685 | ||
| Evidence for a cholinergic mechanism of "learned" changes in the responses of barrel field neurons of the awake and undrugged rat. | Q41227739 | ||
| Effects of flunitrazepam on memory and their reversal by two antagonists. | Q41261490 | ||
| Comparative effects of ibotenic acid- and quisqualic acid-induced lesions of the substantia innominata on attentional function in the rat: further implications for the role of the cholinergic neurons of the nucleus basalis in cognitive processes | Q41300798 | ||
| Modelling dementia: effects of scopolamine on memory and attention | Q41410440 | ||
| Effects of oral scopolamine on human stimulus evaluation | Q41489638 | ||
| Memory decline in the aged: treatment with lecithin and physostigmine | Q41553912 | ||
| Characterizing anticholinergic abuse in community mental health | Q41855533 | ||
| Selective attention skills in Alzheimer's disease: performance on graded cancellation tests varying in density and complexity | Q41911896 | ||
| Sparing of attentional relative to mnemonic function in a subgroup of patients with dementia of the Alzheimer type | Q41963366 | ||
| Signal detection indices in schizophrenics on a visual, auditory, and bimodal Continuous Performance Test | Q42076422 | ||
| Substantia innominata: critical link in the behavioral expression of mesolimbic dopamine stimulation in the rat. | Q42458407 | ||
| A role for acetylcholine in conditioning-related responses of rat frontal cortex neurons: microiontophoretic evidence | Q42458624 | ||
| Electrophysiological studies of acetylcholine and the role of the basal forebrain in the somatosensory cortex of the cat. II. Cortical neurons excited by somatic stimuli | Q42482639 | ||
| Interactions between the effects of basal forebrain lesions and chronic treatment with MDL 26,479 on learning and markers of cholinergic transmission | Q42508037 | ||
| Nucleus basalis stimulation facilitates thalamocortical synaptic transmission in the rat auditory cortex | Q42508161 | ||
| Basal forebrain and frontal cortex neuron responses during visual discrimination in the rat. | Q42510530 | ||
| Heterogeneity and selectivity of the degeneration of cholinergic neurons in the basal forebrain of patients with Alzheimer's disease | Q42510975 | ||
| Nucleus basalis and thalamic control of neocortical activity in the freely moving rat. | Q42514091 | ||
| Long-term enhancement of evoked potentials in cat somatosensory cortex produced by co-activation of the basal forebrain and cutaneous receptors | Q42518973 | ||
| Anxiogenic drugs beta-CCE and FG 7142 increase extracellular dopamine levels in nucleus accumbens | Q43551021 | ||
| Ventral pallidal neuronal responses to dopamine receptor stimulation in the nucleus accumbens | Q43981322 | ||
| The distinction of positive and negative symptoms. The failure of a two-dimensional model | Q43996898 | ||
| The basis for choice reaction time slowing in Alzheimer's disease | Q44071320 | ||
| Toward modeling age-related changes of attentional abilities in rats: simple and choice reaction time tasks and vigilance | Q44715665 | ||
| Models of memory dysfunction? A comparison of the effects of scopolamine and lorazepam on memory, psychomotor performance and mood | Q45719974 | ||
| Cholinergic controversies. | Q45989135 | ||
| Cholinergic modulation of responses to single tones produces tone-specific receptive field alterations in cat auditory cortex | Q46090424 | ||
| Acetylcholine modifies neuronal acoustic rate-level functions in guinea pig auditory cortex by an action at muscarinic receptors | Q46183416 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | senile dementia | Q11610626 |
| schizophrenia | Q41112 | ||
| attention | Q6501338 | ||
| P1104 | number of pages | 12 | |
| P304 | page(s) | 539-550 | |
| P577 | publication date | 1994-05-01 | |
| P1433 | published in | Psychopharmacology | Q1422802 |
| P1476 | title | Neuronal mechanisms of the attentional dysfunctions in senile dementia and schizophrenia: two sides of the same coin? | |
| P478 | volume | 114 |
| Q36681956 | Abnormal neurotransmitter release underlying behavioral and cognitive disorders: toward concepts of dynamic and function-specific dysregulation |
| Q33544991 | Abnormal regulation of corticopetal cholinergic neurons and impaired information processing in neuropsychiatric disorders |
| Q45215142 | Alterations in behavioral responses to a cholinergic agonist in post-pubertal rats with neonatal ventral hippocampal lesions: relationship to changes in muscarinic receptor levels |
| Q34524244 | Aniracetam: its novel therapeutic potential in cerebral dysfunctional disorders based on recent pharmacological discoveries. |
| Q64896885 | Anti-dementia Drugs for Psychopathology and Cognitive Impairment in Schizophrenia: A Systematic Review and Meta-analysis. |
| Q32150995 | Anticholinergicity and cognitive processing in chronic schizophrenia. |
| Q48724431 | Apomorphine-induced hypoattention in rats and reversal of the choice performance impairment by aniracetam |
| Q48111660 | Artificially-reared female rats show reduced prepulse inhibition and deficits in the attentional set shifting task--reversal of effects with maternal-like licking stimulation |
| Q44317519 | Assessment of a combination of physostigmine and scopolamine as pretreatment against the behavioural effects of organophosphates in the common marmoset (Callithrix jacchus). |
| Q34023931 | Attention as a target of intoxication: insights and methods from studies of drug abuse |
| Q27319516 | Basal forebrain control of wakefulness and cortical rhythms |
| Q52210282 | Behavioral vigilance in rats: task validation and effects of age, amphetamine, and benzodiazepine receptor ligands. |
| Q101215918 | Clinicopathological investigation of the background of cognitive decline in elderly schizophrenia |
| Q73138931 | Cognitive functions of cortical acetylcholine: toward a unifying hypothesis |
| Q51114760 | Conditioned and unconditioned stimuli increase frontal cortical and hippocampal acetylcholine release: effects of novelty, habituation, and fear. |
| Q42450209 | Cortical acetylcholine and processing capacity: effects of cortical cholinergic deafferentation on crossmodal divided attention in rats |
| Q33842805 | Cortical cholinergic inputs mediating arousal, attentional processing and dreaming: differential afferent regulation of the basal forebrain by telencephalic and brainstem afferents |
| Q71539033 | Dissociation between the attentional effects of infusions of a benzodiazepine receptor agonist and an inverse agonist into the basal forebrain |
| Q40633295 | Donepezil for memory dysfunction in schizophrenia. |
| Q71539043 | Effect of scopolamine on visual attention in rats |
| Q42633058 | Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study |
| Q48387407 | Effects of lesions of the nucleus basalis magnocellularis on the acquisition of cocaine self-administration in rats. |
| Q41676772 | Effects of nicotinic acetylcholine receptor ligands on behavioral vigilance in rats |
| Q34097595 | Evidence of dopaminergic processing of executive inhibition |
| Q51975637 | Eye movement task measures inhibition and spatial working memory in adults with schizophrenia, ADHD, and a normal comparison group. |
| Q42459801 | GABAergic basal forebrain neurons that express receptor for neurokinin B and send axons to the cerebral cortex |
| Q48337407 | Intra-accumbens infusions of antisense oligodeoxynucleotides to one isoform of glutamic acid decarboxylase mRNA, GAD65, but not to GAD67 mRNA, impairs sustained attention performance in the rat. |
| Q35598427 | Knockout and knockin mice to investigate the role of nicotinic receptors in the central nervous system |
| Q52010922 | Lack of association between schizophrenia and the apolipoprotein E epsilon 4 allele. |
| Q41394773 | Modulation of cognitive processes by transsynaptic activation of the basal forebrain |
| Q42453999 | Morphological and electrophysiological characteristics of noncholinergic basal forebrain neurons |
| Q42458364 | Neural systems underlying arousal and attention. Implications for drug abuse. |
| Q41049144 | Neurobehavioural mechanisms of reward and motivation. |
| Q48024719 | Pharmacology of sensory stimulation-evoked increases in frontal cortical acetylcholine release |
| Q35741065 | Psychopharmacological approaches to modulating attention in the five-choice serial reaction time task: implications for schizophrenia. |
| Q52611036 | Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased. |
| Q34077418 | Regulation of cortical acetylcholine release: insights from in vivo microdialysis studies |
| Q48190552 | Role of accumbens and cortical dopamine receptors in the regulation of cortical acetylcholine release |
| Q36660788 | The emergence and basis of endogenous attention in infancy and early childhood |
| Q34722557 | The neglected constituent of the basal forebrain corticopetal projection system: GABAergic projections |
| Q41376826 | Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers |
| Q30478332 | Wistar-Kyoto rats as an animal model of anxiety vulnerability: support for a hypervigilance hypothesis |
Search more.